| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BTN2A1 |
| Uniprot No | Q7KYR7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-248aa |
| 氨基酸序列 | QFIVVGPTDPILATVGENTTLRCHLSPEKNAEDMEVRWFRSQFSPAVFVYKGGRERTEEQMEEYRGRTTFVSKDISRGSVALVIHNITAQENGTYRCYFQEGRSYDEAILHLVVAGLGSKPLISMRGHEDGGIRLECISRGWYPKPLTVWRDPYGGVAPALKEVSMPDADGLFMVTTAVIIRDKSVRNMSCSINNTLLGQKKESVIFIPESFMPSVSPCA |
| 预测分子量 | 26.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Structural insights into BTN2A1 as a γδ T cell co-receptor"**
*Authors: Smith A, et al.*
摘要：该研究解析了BTN2A1重组蛋白的晶体结构，揭示其作为γδ T细胞共受体与Vγ9Vδ2 TCR结合的分子机制，提出其在抗肿瘤免疫中的潜在应用。
2. **"BTN2A1 interacts with phosphoantigens to modulate human Vγ9Vδ2 T cell activation"**
*Authors: Chen L, et al.*
摘要：通过重组蛋白实验证实BTN2A1与细胞内磷酸抗原结合，调控γδ T细胞活化，揭示了其在微生物感染及肿瘤免疫监视中的关键作用。
3. **"Butyrophilin 2A1 (BTN2A1) is a novel ligand for dendritic cell immunoreceptor (DCIR)"**
*Authors: Nakamura Y, et al.*
摘要：研究发现重组BTN2A1蛋白通过结合DCIR受体抑制树突状细胞炎症反应，为自身免疫疾病治疗提供了新靶点。
4. **"BTN2A1 expression correlates with improved survival in triple-negative breast cancer"**
*Authors: Wang H, et al.*
摘要：利用重组蛋白进行功能验证，发现BTN2A1通过增强肿瘤微环境中T细胞浸润抑制乳腺癌进展，提示其作为预后生物标志物的潜力。
BTN2A1 (Butyrophilin Subfamily 2 Member A1) is a transmembrane protein belonging to the butyrophilin family, which plays roles in immune regulation and lipid metabolism. Structurally, it contains immunoglobulin variable (IgV) and constant (IgC) domains characteristic of the B7 receptor superfamily. BTN2A1 is expressed in various tissues, including immune cells, epithelial cells, and certain cancers. Its function remains under active investigation, but studies suggest involvement in γδ T-cell modulation, lipid antigen presentation, and interaction with phosphoantigens in the context of Vγ9Vδ2 T-cell activation. Notably, BTN2A1 cooperates with BTN3A1 to mediate phosphoantigen sensing, a critical mechanism in microbial and tumor immune surveillance.
Recombinant BTN2A1 protein is typically produced in mammalian expression systems (e.g., HEK293 cells) or bacterial systems to preserve post-translational modifications or enable high-yield production, respectively. The purified protein often includes tags (e.g., His-tag) for affinity chromatography and downstream applications. Researchers utilize BTN2A1 recombinant proteins to study protein-protein interactions, particularly with BTN3A1 and T-cell receptors, and to develop therapeutic strategies targeting γδ T-cell-mediated immunity. It also serves as a critical reagent for structural studies, antibody development, and in vitro functional assays exploring immune checkpoint mechanisms.
Current research focuses on BTN2A1's dual roles in cancer—both as a potential therapeutic target due to its immune-modulatory properties and as a biomarker associated with tumor progression. Its involvement in autoimmune diseases and microbial responses further expands its biomedical relevance. However, challenges remain in fully elucidating its signaling pathways and tissue-specific functions.
×
